Anti-BACE1 Antibody is a humanized monoclonal antibody targeting beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 is a transmembrane aspartic protease and the rate-limiting enzyme for the generation of Aβ peptides in Alzheimer's disease (AD). This antibody functions by specifically binding to the extracellular domain of BACE1, neutralizing its enzymatic activity or inducing receptor internalization to block the beta-site cleavage of amyloid precursor protein (APP). This process effectively reduces the production of toxic Aβ40/42 and inhibits the formation and deposition of amyloid plaques, making it a pivotal tool for researching the pathogenesis and immunotherapeutic strategies of neurodegenerative diseases.